Current:Home > ScamsFDA approves Zepbound, a new obesity drug that will take on Wegovy -ValueMetric
FDA approves Zepbound, a new obesity drug that will take on Wegovy
View
Date:2025-04-19 03:21:33
An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.
Eli Lilly & Co., maker of Zepbound, says it shows greater weight loss at a lower list price than Wegovy. The Lilly drug will be available in the U.S. by the end of the year. A version of the shot, known generically as tirezepatide, is already sold as Mounjaro to treat Type 2 diabetes.
The Lilly drug works by acting on two hormone receptors in the brain, including one called GLP-1, short for glucagon-like peptide-1 – that regulate appetite and metabolism.
The new class of medicines for managing obesity that includes Zepbound and Wegovy has given people with obesity and overweight a potent option for treatment. But the drugs are expensive, and many people who lose weight regain it after stopping the medicines.
Dramatic loss in weight
In clinical trials, the average weight loss for people taking Zepbound was about 20%. One in three users of the medication at its highest dose, saw weight loss of about a quarter of their body weight. The results are roughly equivalent to those of bariatric surgery.
Common side effects from the drug include nausea, diarrhea, constipation and vomiting. The drug also caused thyroid tumors in rats, though the FDA said it's not known if Zepbound causes the same kind of tumors in humans.
In announcing the approval, the FDA cited the growing public health concern over excess weight. "In light of increasing rates of both obesity and overweight in the United States, today's approval addresses an unmet medical need," said Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research. About 70% of adult Americans have obesity or overweight, the FDA noted.
"New treatment options bring hope to the many people with obesity who struggle with this disease," said Joe Nadglowski, president and CEO of the Obesity Action Coalition, in a statement released by Lilly. He noted numerous life-threatening diseases — from heart attacks and strokes to diabetes — that are linked to obesity.
Cost and insurance coverage
New medications to treat obesity and related conditions have become wildly popular, but are expensive, especially when paid for out of pocket.
Zepbound will carry a list price of $1,060, which would make it about 20% less than the list price for Wegovy, Lilly said.
The actual amount patients would pay would depend on their insurance coverage and potential discounts. Insurance coverage for Wegovy, for example, varies widely by provider.
Lilly said people with commercial health insurance that covers Zepbound "may be eligible to pay as low as $25" for one-month or three-month prescriptions.
Lilly will offer a discount card to help defray the expense for people who have commercial health insurance that doesn't include coverage for the drug. The cost could be reduced to $550 for a one-month prescription of Zepbound, or about half the list price, Lilly said.
Medicare doesn't pay for weight-loss drugs. However, Congress is considering measures that would expand insurance access to cover treatments for obesity, including some of the new medications, for Medicare enrollees.
"Far too many hurdles continue to prevent people living with obesity from accessing obesity treatments that could lead to significant weight loss," said Mike Mason, executive vice president and president of Lilly's Diabetes and Obesity division in a statement, calling for the government and insurance industry to cover Zepbound.
veryGood! (5)
Related
- A South Texas lawmaker’s 15
- Insider Q&A: CIA’s chief technologist’s cautious embrace of generative AI
- Mother who said school officials hid her teen’s gender expression appeals judge’s dismissal of case
- Moose kills Alaska man attempting to take photos of her newborn calves
- Sam Taylor
- Ricky Stenhouse could face suspension after throwing punch at Kyle Busch after All-Star Race
- 'Bachelorette' star Ryan Sutter says he and wife Trista are 'fine' amid mysterious posts
- Psst! Pottery Barn’s Memorial Day Sale Has Hundreds of Items up to 50% Off, With Homeware Starting at $4
- Whoopi Goldberg is delightfully vile as Miss Hannigan in ‘Annie’ stage return
- Anne Hathaway's White-Hot Corset Gown Is From Gap—Yes, Really
Ranking
- Daughter of Utah death row inmate navigates complicated dance of grief and healing before execution
- Kandi Burruss Breaks Silence on Real Housewives of Atlanta's Major Cast Shakeup
- Big Ten outpaced SEC with $880 million in revenue for 2023 fiscal year with most schools getting $60.5 million
- Jim Parsons’ Dramatic Response to Potential Big Bang Theory Sequel Defies the Laws of Physics
- Civic engagement nonprofits say democracy needs support in between big elections. Do funders agree?
- Over $450K recovered for workers of California mushroom farms that were sites of fatal shootings
- Anne Hathaway's White-Hot Corset Gown Is From Gap—Yes, Really
- Tori Spelling Reveals Multiple Stomach Piercings She Got as a Gift From Her Kids
Recommendation
Daughter of Utah death row inmate navigates complicated dance of grief and healing before execution
Supreme Court turns away challenge to Maryland assault weapons ban
Is that ‘Her’? OpenAI pauses a ChatGPT voice after some say it sounds like Scarlett Johansson
CANNES DIARY: Behind the scenes of the 2024 film festival
Sonya Massey's family keeps eyes on 'full justice' one month after shooting
Texas bridge connecting Galveston and Pelican Island reopened after barge collision
Auburn running back Brian Battie on ventilator after weekend shooting in Florida, coach says
Alien-like creature discovered on Oregon beach